よむ、つかう、まなぶ。
資料3-3 カルボプラチン (19 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000198856_00031.html |
| 出典情報 | 医療上の必要性の高い未承認薬・適応外薬検討会議（第57回 ） |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
7) Kiess AP, Damast S, Makker V, et al. Five-year outcomes of adjuvant carboplatin/paclitaxel
chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer.
Gynecol Oncol. 2012;127(2):321-5.
8) Dietrich CS 3rd, Modesitt SC, DePriest PD, et al. The efficacy of adjuvant platinum-based
chemotherapy in Stage I uterine papillary serous carcinoma (UPSC). Gynecol
Oncol. 2005;99(3):557-63.
9) Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO Consensus Conference on
Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol. 2016;27(1):16-41.
10) Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management
of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021;31(1):12-39.
11) de Boer SM, Powell ME, Mileshkin L, et al. PORTEC Study Group. Adjuvant
chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer
(PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3
trial. Lancet Oncol. 2019;20(9):1273-85.
12) Matei D, Filiaci V, Randall ME, et al. Adjuvant Chemotherapy plus Radiation for Locally
Advanced Endometrial Cancer. N Engl J Med. 2019;380(24):2317-26.
13) Miller DS, Filiaci VL, Mannel RS, et al. Carboplatin and Paclitaxel for Advanced Endometrial
Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG
Oncology/GOG0209). J Clin Oncol. 2020;38(33):3841-50.
14) de Boer SM, Powell ME, MileshkinL, et al. Adjuvant chemoradiotherapy versus radiotherapy
alone for women with high-risk endometrial cancer (PORTEC-3): final results of an
international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19(3):295309.
15) Powell MA, Filiaci VL, Hensley ML, et al. A randomized phase 3 trial of paclitaxel (P) plus
carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naive patients with stage
I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG Oncology trial. J
Clin Oncol. 2019;37(15)_suppl 5500[abstract].
16) Powell MA, Filiaci VL, Hensley ML, et al. Randomized Phase III Trial of Paclitaxel and
Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or
Ovary: An NRG Oncology Trial. J Clin Oncol. 2022;40(9):968-77.
17) Nomura H ,Aoki D, Michimae H, et al. Effect of Taxane Plus Platinum Regimens vs
Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk
of Progression: A Randomized Clinical Trial. JAMA Oncol. 2019;5(6):833-40.
18) Morice P, Leary A, Creutzberg C, et al. Endometrial cancer. Lancet. 2016;387(10023):1094108.
19) Karen H. L, and Russell R. B. Endometrial cancer. N Engl J Med 2020;383:2053-64.
19
chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer.
Gynecol Oncol. 2012;127(2):321-5.
8) Dietrich CS 3rd, Modesitt SC, DePriest PD, et al. The efficacy of adjuvant platinum-based
chemotherapy in Stage I uterine papillary serous carcinoma (UPSC). Gynecol
Oncol. 2005;99(3):557-63.
9) Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO Consensus Conference on
Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol. 2016;27(1):16-41.
10) Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management
of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021;31(1):12-39.
11) de Boer SM, Powell ME, Mileshkin L, et al. PORTEC Study Group. Adjuvant
chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer
(PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3
trial. Lancet Oncol. 2019;20(9):1273-85.
12) Matei D, Filiaci V, Randall ME, et al. Adjuvant Chemotherapy plus Radiation for Locally
Advanced Endometrial Cancer. N Engl J Med. 2019;380(24):2317-26.
13) Miller DS, Filiaci VL, Mannel RS, et al. Carboplatin and Paclitaxel for Advanced Endometrial
Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG
Oncology/GOG0209). J Clin Oncol. 2020;38(33):3841-50.
14) de Boer SM, Powell ME, MileshkinL, et al. Adjuvant chemoradiotherapy versus radiotherapy
alone for women with high-risk endometrial cancer (PORTEC-3): final results of an
international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19(3):295309.
15) Powell MA, Filiaci VL, Hensley ML, et al. A randomized phase 3 trial of paclitaxel (P) plus
carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naive patients with stage
I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG Oncology trial. J
Clin Oncol. 2019;37(15)_suppl 5500[abstract].
16) Powell MA, Filiaci VL, Hensley ML, et al. Randomized Phase III Trial of Paclitaxel and
Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or
Ovary: An NRG Oncology Trial. J Clin Oncol. 2022;40(9):968-77.
17) Nomura H ,Aoki D, Michimae H, et al. Effect of Taxane Plus Platinum Regimens vs
Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk
of Progression: A Randomized Clinical Trial. JAMA Oncol. 2019;5(6):833-40.
18) Morice P, Leary A, Creutzberg C, et al. Endometrial cancer. Lancet. 2016;387(10023):1094108.
19) Karen H. L, and Russell R. B. Endometrial cancer. N Engl J Med 2020;383:2053-64.
19